CClinicalTrials.gg
CompletedNCT05225649Updated Nov 8, 2024

Health e-Baby: Trial to Reduce Obesity Risk Factors During the First 1,000 Days

An interventional study of Behavior Change Intervention in Obesity, Infant, sponsored by Columbia University. Completed at 1 site in United States. Open to female participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-11-08.

Sponsored by Columbia University · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
Female
01

Study summary

Specific Aim: Feasibility of a Pilot Randomized Controlled Trial (RCT) in Pregnancy and Infancy to Reduce Childhood Obesity Risk Factors in Early Life.

The main outcomes are feasibility of the intervention components and data collection. Study will use maternal body mass index (BMI) and child weight-for-length outcomes to estimate sample size needed for a full-scale trial to test intervention efficacy. Primary analysis for full-scale trial power and sample size calculations will be conducted using child weight-for-length data at Child Age 12 Months Visit. Data collected will inform future interventions.

Read the detailed description

Early life interventions to prevent childhood obesity among disproportionately burdened populations are needed to reduce childhood obesity.

The overall goal of this study is to test the feasibility of a pilot randomized controlled trial to promote healthy maternal weight in pregnancy and post-partum and normal child weight-for-length from birth to age 12 months. The study will include 50 women (enrollment up to 70 to account for potential attrition) in pregnancy and their child through age 12 months to examine rates of study component completion, study component satisfaction, and retention. Women enrolled in the intervention will participate in virtual health coaching and receive self-directed behavior change materials by text and email. The results of this study will help us develop efficacious childhood obesity prevention interventions and determine how many study participants would be needed for a full-scale trial. Ultimately, this research could open new avenues for studying ways to promote health starting early in life.

02

Conditions studied

  • Obesity, Infant

Keywords

  • First 1,000 days
  • Mobile Health
  • Behavior Change Intervention
03

In context

Obesity

6,296 studies on the registry are indexed under Obesity; 1,692 are open to participants now.

This study's enrollment of 50 is below the median of 78 across 4,878 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Columbia University is the lead sponsor of 1,103 studies on the registry; 193 are open to participants now.

Of its 172 completed or terminated interventional studies of FDA-regulated products, 142 (83%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Inclusion criteria

  • Age 18-50 years at time of enrollment
  • Gestational age 10-20 weeks at time of enrollment
  • Receiving primary care or prenatal care at Columbia/New-York Presbyterian site
  • Planned delivery at Columbia/New-York Presbyterian with planned continuation of primary care (postpartum and pediatric) at Columbia/New-York Presbyterian
  • Ability to read and respond to questions in English or Spanish
  • Smart phone ownership
  • Willingness to receive information by smart phone for 18-month intervention and follow-up duration
  • Willingness to be randomized into an observational study or an intervention and complete all study components
  • Gives permission to participate in receiving messages to their smart phone and email
  • Gives permission to complete all study procedures
  • Has a physician's clearance for light to moderate physical activity
  • Has an active email address
  • Capable of providing informed consent
  • Has access to Wi-Fi connection in their household

Exclusion criteria

Exclusion Criteria:

  • Multiple gestation
  • Pre-pregnancy body mass index \<18.5 kg/m2 >40
  • Major fetal anomaly
  • Fetal genetic abnormality
  • Planned termination of pregnancy
  • Chronic medical conditions that affect nutrition or prohibit regular exercise or alter weight status such as:
  • Diseases associated with glucose metabolism
  • Diabetes (Type 1, type 2)
  • Inflammatory Bowel Disease (Crohn's disease, ulcerative colitis)
  • History of gastric bypass/gastric sleeve
  • Uncontrolled thyroid disease (hypo or hyperthyroidism)
  • Condition requiring enteral tube feeding
  • Congenital or acquired heart disease that impacts nutritional needs and physical activity ability
  • HIV/AIDS
  • Kidney disease
  • Cancer
  • Uncontrolled autoimmune disease
  • Lupus
  • Multiple sclerosis
  • Sickle cell disease
  • Zika infection
  • Taking or planning to take certain prescription medications including high dose glucocorticoids, atypical antipsychotics associated with weight gain (such as risperdal (risperidone), clozapine (clozaril), olanzapine (zyprexa), quetiapine (seroquel), etc.), or other prescription weight loss medications
  • Personal history of breast cancer or any other type of cancer other than a basal cell skin cancer
  • Personal history of cardiovascular disease (coronary artery disease, congestive heart failure, valvular heart disease, stroke, transient ischemic attack, or intermittent claudication), kidney disease, liver disease, venous or arterial thromboembolic disease, adrenal insufficiency, depression requiring hospitalization within the past 6 months, or non-pregnancy related illness requiring overnight hospitalization in the past 6 months
  • Underlying disease/treatment that might interfere with participation in/completion of the study (e.g., significant gastrointestinal conditions, major psychiatric disorders, and others at the discretion of the study clinician)
  • Other active medical problems detected by examination or laboratory testing
  • Inability to complete study visits or intervention components
  • Unwillingness or inability to commit to a 18-month research study for them or their child, including plans to move away
  • Plans to be in a different geographic area within the next 2 years
  • Unable to give informed consent
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Care provider, Investigator, Outcomes assessor)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    Behavior Change Intervention

    Participants will receive health coaching, patient-directed behavior change support by mobile health, and usual clinical care.

    Behavioral: Behavior Change Intervention

  • No intervention
    Control

    Participants will receive usual clinical care.

Interventions

  • BehavioralBehavior Change Intervention

    Health coaching sessions; self-monitoring: Fitbit, home scale, and app; personalized health information by mobile health: growth charts and age-specific health behavior information via text message and email; behavior change support by mobile health: family-based health behavior goal setting via chatbot; and usual clinical care.

06

What researchers measure

Primary outcomes

  1. Arm specific retention rates at 18 months

    The retention rate will be defined as the proportion of enrolled individuals who complete infant age 12-months study visits (study month 18) according to each arm.

    Time frame: Up to 18 months

07

Study locations

1 site
  • Columbia University
    New York, New York 10032, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 8, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05225649
Lead sponsor
Columbia University
Collaborators
Doris Duke Charitable Foundation
Responsible party
Sponsor
First posted
Feb 4, 2022
Start date
Jan 14, 2022
Primary completion
Sep 1, 2024
Completion
Sep 1, 2024
Last update
Nov 8, 2024

Study contacts

Ali Mencin, MD
principal investigator · Columbia University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion